The long-term efficacy and safety of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes, who had been treated with a glinid.

The long-term efficacy and safety of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes, who had been treated with a glinid. - SINGLE Study 2 (Extension Study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000005291

Enrollment

Registered

2011-04-01

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes treated with sitagliptin. Patients enrolled in the SINGLE Study.

Exclusion criteria

Exclusion criteria: Patients with moderate to severe renal insufficiency

Design outcomes

Primary

Measure	Time frame
HbA1c, Glycoalbumin, 1,5-AG, plasma glucose	—

Secondary

Measure	Time frame
Serum C-peptide, IRI, IRG, HOMA, SUIT index, CPR index, proinsulin/insulin, Body weight	—

Countries

Japan

Outcome results